Issuer-Sponsored Content from MAIA Biotechnology*

The Fed did exactly what everyone expected yesterday, and the market mostly yawned. But digging around this morning, one stock stood out to me based on how it’s been trading and who’s been buying. I’m watching it closely again today.

TODAY’S TOP ALERT! 

MAIA Biotechnology (NYSE: MAIA)

👉  MAIA is TODAY’S #1 ALERT* 👈

Hey Folks, Jeff Bishop here,

As expected, the Fed left rates steady yesterday, and Jerome Powell delivered what CNBC calls “a snoozer” of a press conference in the afternoon.

The Fed likes to meet market expectations, and yesterday it did just that. 

As a result, stocks finished the session basically flat. This morning, though, futures are inching higher as investors shift their focus back to tech earnings.

One stock that has decidedly not been flat is one of my all-time-favorite “tactical” ideas…

If you’ve been following me for a while, you’ve seen me talk about this one many times over the last year.

And for good reason.

You see, over the past two months, this stock has roared 227%.

💥Go ahead and cue up MAIA Biotechnology, Inc. (MAIA)* on your screen.

I’m pleased to say I alerted this ripper on two separate occasions in early December…

On December 1, the stock jumped as high as 21% intraday, and on December 9, it ripped as high as 17%. I sent follow-up alerts on December 10 and 11, and the stock made a peak move from December 9–11 of 34%.

MAIA made double-digit intraday moves all eleven times I alerted in earlier 2025 as well.

It began its latest leg up around January 13, and from there through yesterday’s close, it has climbed 84%.

What clued me into all this great price action was the relentless buying from company insiders. Since November 21, they’ve scooped up 375,922 shares:

That’s the biggest “tell” with clinical-stage pharma stocks like MAIA. Nobody knows better than company insiders how things are going.

And sure enough, on December 10, MAIA announced that its lead drug candidate, ateganosine (THIO), is now aiming squarely at the $50 billion immunotherapy market for non-small cell lung cancer. 

The company believes ateganosine’s novel mechanism — targeting telomeres and activating immune response — could position it as a best-in-class treatment for late-stage patients. 

The next day, we learned that MAIA had dosed its first patient in the “THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine administered in sequence with a checkpoint inhibitor (CPI) as a third-line treatment for advanced non-small cell lung cancer (NSCLC).”

CEO Vlad Vitoc said “This larger trial will provide us a robust dataset to support our case for commercial approval by the U.S. FDA.”

The company also reminded us that the FDA “has granted Fast Track designation for ateganosine for the treatment of NSCLC.”

The latest news came last Tuesday when the company provided a corporate update on 2025 achievements and laid out its 2026 milestones. Some highlights:

• CEO Vlad Vitoc said, “Our statistical assessments of ateganosine imply a high probability of technical success in our concurrent Phase 3 and Phase 2 trials.” [emphasis added]

• He added that ateganosine is advancing “toward potential early commercial approval — possibly within 18 to 24 months” [emphasis added]

• The company said it anticipates “Initial measures of efficacy from Phase 3 study” and the “Conclusion of Part C of Phase 2 study” in 2026

The stock ripped even higher on the news, but it’s the price action yesterday that has me dialed in right now…

It kicked off the day gaining 8% before sellers stepped in and the stock closed down 5.7%.

We’re now at a more attractive price level, and the stock has clearly tested higher highs. That’s why I’m watching it today to see if we get another jump up.

👉  MAIA is TODAY’S #1 ALERT 👈*

MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.

Here are some highlights you should consider as you do your own homework on the company right now…

1. A Potential Game-Changer in Cancer Treatment

MAIA’s flagship product, THIO (christened "ateganosine" last March), is a potential game changer in oncology.

The company describes ateganosine as “a potentially first-in-class small molecule that is the only direct telomere targeting agent currently in clinical development.”

Telomeres are like protective caps at the ends of chromosomes that cancer cells exploit to keep dividing endlessly. 

Ateganosine breaks down these caps, triggering rapid cancer cell death while activating the immune system to keep fighting even after treatment stops.

This dual-action approach could revolutionize how we think about cancer therapies. Most existing treatments target the immune system or the cancer cells — not both.

On July 17, MAIA revealed the publication of preclinical data in a leading peer-reviewed journal, Nucleic Acids Research, demonstrating Ateganosine had “a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies.”

On August 27, the company said it had published developments in its Phase 2 THIO-101 clinical trial in a special issue of the journal Cells called “Cellular Mechanisms of Anti-Cancer Therapies.”

Then on October 23, the company released details of “exceptional extended survival in third-line [non-small cell lung cancer] patients.”

MAIA CEO Vlad Vitoc said that, “as of September 17, 2025, a patient that began therapy in March 2023 has shown survival of 30 months, or 912 days, an outstanding measure relative to many of the high-risk cancers.”

And on November 21, the company announced highlights from presentations at the Society for Immunotherapy of Cancer annual conference. 

Mr. Vitoc said that based on study results to date, “we believe that our Phase 3 trial could lead to an early commercial approval of ateganosine by the FDA.” [emphasis added]

As mentioned, in December MAIA announced dosing its first patient in the THIO-104 Phase 3 pivotal trial evaluating the efficacy of ateganosine in sequence with a checkpoint inhibitor (CPI) in third-line NSCLC.

2. FDA Orphan Drug and Fast Track Designations

In the biotech world, exclusivity is crucial. MAIA’s Ateganosine has Orphan Drug Designations from the FDA for small cell lung cancer (SCLC), hepatocellular carcinoma, and glioblastoma. 

This would mean 7 years of market exclusivity post-approval plus tax credits for clinical trial costs.

On July 28, MAIA revealed:

CEO Vlad Vitoc noted that “If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.” [emphasis added]

For perspective, there are more than 226,000 new cases of lung cancer (SCLC + NSCLC) alone in the U.S. each year, and “Lung cancer is by far the leading cause of cancer death in the US, accounting for about 1 in 5 of all cancer deaths.” 

If MAIA’s drug proves effective, it could dominate a potentially lucrative market.

3. Strong Early Data Is Turning Heads

Updated data from its THIO-101 Phase 2 trial — released on September 11 — were incredibly promising. 

In a heavily pre-treated population, Ateganosine paired with Regeneron’s Libtayo achieved progression-free survival (PFS) of 5.6 months — more than double the 2.5 months for the comparable standard-of-care.

MAIA’s CEO said the data demonstrate “the durability of ateganosine treatment through extended treatment cycles, which is in line with consistent tolerability and low toxicity.”

Results like these can attract big pharma partnerships and investor interest. Ateganosine is showing real potential to disrupt the market.

💥Also in September, the National Institutes of Health awarded MAIA a $2.3 million grant for the expansion of THIO-101.

They don’t hand those out to just anyone, folks.

MAIA’s senior medical director, Victor Zaporojan, called the grant “a tremendous achievement and a testament to the dedication, collaboration, and hard work of everyone involved in the clinical development of ateganosine.”

4. Partnership with Roche 🤝

On June 18, MAIA revealed a clinical master supply agreement with Roche (yes, ~$346 billion market cap Roche) “for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.”

The two drugs were found to be “highly synergistic” in preclinical studies.

Between this and the Regeneron (~$79 billion market cap) partnerships, MAIA’s Ateganosine has attracted attention from some serious pharma heavyweights. 🥊

5. Strong Insider Confidence 💼

Company insiders aren’t just talking, they’re buying MAIA shares hand over fist lately.

I mentioned the more than 196,000 shares bought since November 21, but going back to November 2024, insiders combined have bought more than a million shares.

Why It Stands Out:

With a truly novel approach to cancer, strong early data, and heavyweight partnerships, MAIA could be on the verge of something game-changing. 

In August, Diamond Equity Research released an update note on MAIA highlighting “[r]ecent updates [that] further de-risk the THIO program in third-line [non-small cell lung cancer].”

Incorporating the company’s recent financials, Diamond revised its sponsored valuation of MAIA to $10.27 per share — 269% higher than yesterday’s closing price.

Investors looking for exposure to next-gen cancer therapies should do their homework on MAIA immediately, beginning with the company website, as well as this investor presentation released just this month.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well, so you are aware of our compensation and other conflicts of interest, as well as additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: I alerted MAIA on 13 occasions in 2025 when it went on to make double-digit gains the same day.

The stock has ripped 227% over the last two months, and after reaching for a new high yesterday before closing the day down, I’m watching to see if it jumps again today.

💥Stay locked into MAIA for all the action!

To Your Success,